(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-03719a-2022-09-30T09:41:29+01:00",
    "date": "2022-09-30T09:41:29+01:00",
    "ocid": "ocds-h6vhtk-03719a",
    "initiationType": "tender",
    "tender": {
        "id": "DN621813",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "(NU/1433-37) NewCo: The Provision of Business Consultancy to Assist Commercialisation of University Research.",
        "status": "complete",
        "classification": {
            "scheme": "CPV",
            "id": "79400000",
            "description": "Business and management consultancy and related services"
        },
        "mainProcurementCategory": "services",
        "description": "Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively. The initial brief of the executive will be to: Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck; Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board Phase (3) January 2023-March 2023 - a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University; b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO. c. Provide to the University of Bath all matters necessary for Research England reporting requirements. Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.",
        "lots": [
            {
                "id": "1",
                "description": "Cancer and neurodegenerative diseases represent major unmet medical needs. It is estimated that approximately 20% of oncogenes are transcription factors (TFs) and many are critical for carcinogenesis. The global Cancer Drugs market was valued at US$92Bn in 2019 and is expected to reach US$124Bn by the end of 2026. The global neurodegenerative diseases drugs market size was valued at US$35.5Bn Million in 2018 and is projected to reach US$63Bn by the end of 2026. Specifically, we plan to target three cancer related TFs, (ATF4 CREB, and ID1) which are implicated in a range of cancer types that include glioma, breast cancer, acute myeloid leukaemia, and the aggregation of a-synuclein and amyloid implicated in Parkinson's Disease and Alzheimer's disease respectively. The initial brief of the executive will be to: Phase (1) September 2022 - December 2022 - Work with Jody Mason and Uni TT team to review current targets, oversee screening programme and lead candidates and produce a viable 5-year business plan and associated pitch deck; Phase (2)September 2022 - December 2022 - Navigate University approval process, work with TT team to get approval from the University Commercialisation Executive Board Phase (3) January 2023-March 2023 - a. Act for the company in the spin out legal process and review the Articles of Association, Shareholder's agreement and IP licence put together by the University; b. Work with the Unit TT team to obtain founder academics' and University approval for appointment as CEO. c. Provide to the University of Bath all matters necessary for Research England reporting requirements. Phase (4) January 2023-June 2023 - Pitch to investors alongside Jody Mason, secure seed finance, draft and submit Innovate UK proposal for preclinical funding Phase (5) The outcome of Phase 4 will provide seed finance and IUK funding for preclinical studies, which will be sufficient to employ the executive and drive preclinical development. The appointment of the executive as CEO will be at the discretion of the board and the University of Bath and will be subject to confirmation, typically at Stage 4 above.",
                "awardCriteria": {
                    "criteria": [
                        {
                            "name": "Ability to meet the required job description",
                            "type": "quality",
                            "description": "Pass/Fail"
                        },
                        {
                            "name": "Quality: Ability to meet the Job Description",
                            "type": "quality",
                            "description": "Pass/Fail and 60%"
                        },
                        {
                            "name": "Equity",
                            "type": "quality",
                            "description": "Pass/Fail"
                        },
                        {
                            "type": "price",
                            "description": "40"
                        }
                    ]
                },
                "hasOptions": false,
                "status": "cancelled"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UKC"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "procurementMethod": "selective",
        "procurementMethodDetails": "Restricted procedure",
        "techniques": {
            "hasDynamicPurchasingSystem": true
        },
        "reviewDetails": "The University will incorporate a standstill period at the point information on the award of the contract is communicated to tenderers. That notification will provide full information on the award decision. The standstill period, which will be for a minimum of 10 calendar days, provides time for unsuccessful tenderers to challenge the award decision before the contract is entered into. The Public Contracts Regulations 2015 (SI 2015 No 102) provide for aggrieved parties who have been harmed or are at risk of harm by a breach of the rules to take action in the High Court (England, Wales and Northern Ireland) within 30 days of knowledge or constructive knowledge of breach."
    },
    "awards": [
        {
            "id": "027417-2022-(NU/1433-37)-1",
            "relatedLots": [
                "1"
            ],
            "status": "active",
            "suppliers": [
                {
                    "id": "GB-FTS-64802",
                    "name": "Cambridge Drug Discovery"
                }
            ]
        }
    ],
    "parties": [
        {
            "id": "GB-FTS-168",
            "name": "Newcastle University",
            "identifier": {
                "legalName": "Newcastle University"
            },
            "address": {
                "streetAddress": "Newcastle University, Procurement Services, Kingsgate",
                "locality": "Newcastle",
                "region": "UKC",
                "postalCode": "NE1 7RU",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Mrs Natalie Morton",
                "telephone": "+44 1912086396",
                "email": "natalie.morton@ncl.ac.uk"
            },
            "roles": [
                "buyer",
                "centralPurchasingBody"
            ],
            "details": {
                "url": "https://www.ncl.ac.uk",
                "buyerProfile": "https://www.ncl.ac.uk",
                "classifications": [
                    {
                        "scheme": "TED_CA_TYPE",
                        "id": "BODY_PUBLIC",
                        "description": "Body governed by public law"
                    },
                    {
                        "scheme": "COFOG",
                        "id": "09",
                        "description": "Education"
                    }
                ]
            }
        },
        {
            "id": "GB-FTS-169",
            "name": "Durham University",
            "identifier": {
                "legalName": "Durham University"
            },
            "address": {
                "locality": "The Palatine Centre, Stockton Road",
                "region": "UKC",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "Edwin.e.milligan@durham.ac.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.durham.ac.uk"
            }
        },
        {
            "id": "GB-FTS-64801",
            "name": "Northumbria University Newcastle Newcastle",
            "identifier": {
                "legalName": "Northumbria University Newcastle Newcastle"
            },
            "address": {
                "locality": "Newcastle upon Tyne",
                "region": "UKC",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "Hugh.Rhodes@northumbria.ac.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://northumbria.ac.uk"
            }
        },
        {
            "id": "GB-FTS-171",
            "name": "University of Sunderland",
            "identifier": {
                "legalName": "University of Sunderland"
            },
            "address": {
                "locality": "Sunderland",
                "region": "UKC",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "Cheryl.Holmstrom@sunderland.ac.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://Sunderland.ac.uk"
            }
        },
        {
            "id": "GB-FTS-38690",
            "name": "Teesside University",
            "identifier": {
                "legalName": "Teesside University"
            },
            "address": {
                "locality": "Middlesbrough, Tees Valley",
                "region": "UKC",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "David.Pratt@tees.ac.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.tees.ac.uk/"
            }
        },
        {
            "id": "GB-FTS-38691",
            "name": "University of Bath on behalf of the SETsquared",
            "identifier": {
                "legalName": "University of Bath on behalf of the SETsquared"
            },
            "address": {
                "locality": "Claverton Down, Bath",
                "region": "UK",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "email": "pb487@bath.ac.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.bath.ac.uk/"
            }
        },
        {
            "id": "GB-FTS-172",
            "name": "European Union",
            "roles": [
                "funder"
            ]
        },
        {
            "id": "GB-FTS-64802",
            "name": "Cambridge Drug Discovery",
            "identifier": {
                "legalName": "Cambridge Drug Discovery"
            },
            "address": {
                "streetAddress": "35 Tunwells Lane, Great Shelford,",
                "locality": "Cambridgeshire",
                "region": "UKC",
                "postalCode": "CB22 5LJ",
                "countryName": "United Kingdom"
            },
            "roles": [
                "supplier"
            ],
            "details": {
                "scale": "sme"
            }
        },
        {
            "id": "GB-FTS-174",
            "name": "Newcastle University",
            "identifier": {
                "legalName": "Newcastle University"
            },
            "address": {
                "locality": "Tyne and Wear",
                "postalCode": "NE1 7RU",
                "countryName": "United Kingdom"
            },
            "roles": [
                "reviewBody"
            ]
        },
        {
            "id": "GB-FTS-1062",
            "name": "Newcastle University",
            "identifier": {
                "legalName": "Newcastle University"
            },
            "address": {
                "locality": "Tyne and Wear",
                "countryName": "United Kingdom"
            },
            "roles": [
                "mediationBody",
                "reviewContactPoint"
            ]
        }
    ],
    "buyer": {
        "id": "GB-FTS-168",
        "name": "Newcastle University"
    },
    "planning": {
        "budget": {
            "finance": [
                {
                    "id": "1",
                    "description": "Northern Accelerator programme involving funding from both the European Regional Development Funding (ERDF) and Research England",
                    "financingParty": {
                        "name": "European Union",
                        "id": "GB-FTS-172"
                    },
                    "relatedLots": [
                        "1"
                    ]
                }
            ]
        }
    },
    "contracts": [
        {
            "id": "027417-2022-(NU/1433-37)-1",
            "awardID": "027417-2022-(NU/1433-37)-1",
            "status": "active",
            "value": {
                "amount": 30000,
                "currency": "GBP"
            },
            "dateSigned": "2022-09-21T00:00:00+01:00"
        }
    ],
    "bids": {
        "statistics": [
            {
                "id": "1",
                "measure": "bids",
                "relatedLot": "1",
                "value": 3
            },
            {
                "id": "2",
                "measure": "smeBids",
                "relatedLot": "1",
                "value": 3
            },
            {
                "id": "3",
                "measure": "foreignBidsFromEU",
                "relatedLot": "1",
                "value": 0
            },
            {
                "id": "4",
                "measure": "foreignBidsFromNonEU",
                "relatedLot": "1",
                "value": 3
            },
            {
                "id": "5",
                "measure": "electronicBids",
                "relatedLot": "1",
                "value": 3
            }
        ]
    },
    "links": [
        {
            "rel": "prev",
            "href": "https://ted.europa.eu/udl?uri=TED:NOTICE:528050-2022:TEXT:EN:HTML"
        }
    ],
    "language": "en"
}